Exchange: NASDAQ·Updated 07:56 PM EDT
News
all
press releases
Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.read more...
Benzinga
More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of theirread more...
Benzinga
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance
The drop follows four straight days of the stock closing in the green.
Stocktwits
Scalable Biotech Manufacturing Unlocks a $14B Market
Scalable Biotech Manufacturing Unlocks a $14B Market Scalable Biotech Manufacturing Unlocks a $14B Market PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of Ava Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary The global cell therapy manufacturing...
PR Newswire
Why Did MBRX Stock Climb 14% Today?
Moleculin Biotech said on Wednesday that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.
Stocktwits
Why Did MBRX Stock Plummet Over 25% Today?
Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.
Stocktwits
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...
PR Newswire
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup
The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.
Stocktwits
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.
Stocktwits

Advertisement|Remove ads.